ライフサイエンスコーパス: cardioverter

1 of cardiac resynchronization therapy with a cardioverter defibrillator (CRT-D) on the effect of ICD

2 ore and after implantation of an implantable cardioverter defibrillator (ICD) and include promotion o

3 ften avoided after receipt of an implantable cardioverter defibrillator (ICD) because of fears that e

4 Patients with an implantable cardioverter defibrillator (ICD) had tachycardia therapi

5 survival benefit of prophylactic implantable cardioverter defibrillator (ICD) implantation in early s

6 showed a survival benefit of the implantable cardioverter defibrillator (ICD) in males with arrhythmo

7 se of CRT in combination with an implantable cardioverter defibrillator (ICD) in patients who are eli

8 Data evaluating the implantable cardioverter defibrillator (ICD) in this patient populat

9 The implantable-cardioverter defibrillator (ICD) lead is the most vulner

10 netic resonance (MR)-conditional implantable cardioverter defibrillator (ICD) systems have become ava

11 To our knowledge, whether implantable cardioverter defibrillator (ICD) therapy improves surviv

12 neity of LGE predict appropriate implantable cardioverter defibrillator (ICD) therapy in ischemic car

13 icant reduction in inappropriate implantable cardioverter defibrillator (ICD) therapy in patients pro

14 ients randomized to CRT-D versus implantable cardioverter defibrillator (ICD) were compared within th

15 ith defibrillator (CRT-D) versus implantable cardioverter defibrillator (ICD), and outcomes.

16 ], 1.21 [95% CI, 1.17-1.25]), no implantable cardioverter defibrillator (OR, 1.46 [95% CI, 1.34-1.55]

17 rly adoption of the subcutaneous implantable cardioverter defibrillator (S-ICD) in the United States

18 a on the safety and efficacy of the wearable cardioverter defibrillator (WCD) in a real-world setting

19 ar fibrillation; and n=8 without implantable cardioverter defibrillator although with symptomatic com

20 verse events, drug continuation, implantable cardioverter defibrillator and cardiac resynchronization

21 rms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopat

22 The implantable cardioverter defibrillator appropriate intervention rate

23 iate analysis showed that in the implantable cardioverter defibrillator arm, each 10-mm Hg decrement

24 ggested for effect modification (implantable cardioverter defibrillator at baseline, left ventricular

25 nd CRT with defibrillator versus implantable cardioverter defibrillator benefit was assessed in multi

26 important criterion to determine implantable cardioverter defibrillator candidacy.

27 th LVEF <=35%, who are potential implantable cardioverter defibrillator candidates, treated with dofe

28 ardiac resynchronization therapy implantable cardioverter defibrillator for the treatment of heart fa

29 quency of palpitation (P=0.004), implantable cardioverter defibrillator implantation (P=0.021), lower

30 nificant complication related to implantable cardioverter defibrillator implantation in comparison wi

31 who are the best candidates for implantable cardioverter defibrillator implantation is one of the mo

32 vation require further study but implantable cardioverter defibrillator implantation should not be gu

33 udden death who may benefit from implantable cardioverter defibrillator implantation.

34 ave a preexisting indication for implantable cardioverter defibrillator implantation.

35 nes only recommend the use of an implantable cardioverter defibrillator in patients with dilated card

36 20 ms) receiving either CRT-D or implantable cardioverter defibrillator in subgroups according to QRS

37 s and shared decision making for implantable cardioverter defibrillator insertion.

38 complications and inappropriate implantable cardioverter defibrillator interventions.

39 Implantable cardioverter defibrillator is the only proven lifesaving

40 with persistent AF, dual-chamber implantable cardioverter defibrillator or cardiac resynchronization

41 results in approximately 130 000 implantable cardioverter defibrillator placements at a cost of >$3 b

42 Medicare patients from the Implantable Cardioverter Defibrillator Registry (January 1, 2005, th

43 e competing risks of appropriate implantable cardioverter defibrillator shock versus mortality.

44 the ventricular rate out of the implantable cardioverter defibrillator shock zone.

45 Reduction was observed for both implantable cardioverter defibrillator shocks and antitachycardia pa

46 with previous cardiac arrest and implantable cardioverter defibrillator shocks for ventricular fibril

47 symptoms and reduces appropriate implantable cardioverter defibrillator shocks.

48 ring AF to prevent inappropriate implantable cardioverter defibrillator shocks.

49 f VT were defined as appropriate implantable cardioverter defibrillator therapies or on the basis of

50 n cardiac arrest, 40 appropriate implantable cardioverter defibrillator therapies).

51 e studied (6 month preprocedural implantable cardioverter defibrillator therapies: median 19 ATP even

52 her risk of mortality or HF with implantable cardioverter defibrillator therapy alone.

53 e less likely to be referred for implantable cardioverter defibrillator therapy despite current guide

54 of patients received appropriate implantable cardioverter defibrillator therapy during medium-term fo

55 n cardiac death, and appropriate implantable cardioverter defibrillator therapy was noted.

56 in the selection of patients for implantable cardioverter defibrillator therapy.

57 y gain longevity from successful implantable cardioverter defibrillator therapy.

58 en cardiac arrest or appropriate implantable cardioverter defibrillator therapy.

59 patients with heart failure for implantable cardioverter defibrillator therapy.

60 An intracardiac cardioverter defibrillator was implanted in 31 patients,

61 Treatment with implantable cardioverter defibrillator was rare (3%) and resulted in

62 ependence on a pacemaker with an implantable cardioverter defibrillator without asynchronous pacing c

63 ]), and survivors more often had implantable cardioverter defibrillator's implanted (OR, 2.1 [1.2-3.6

64 thmia, implantation of pacemaker/implantable cardioverter defibrillator, acute myocardial infarction,

65 ents who are not eligible for an implantable cardioverter defibrillator, and suggests that the WCD ca

66 action 35% or less, an automatic implantable cardioverter defibrillator, and who were ineligible for

67 AF with LVEF <=35% without prior implantable cardioverter defibrillator, cardiac resynchronization th

68 ntitachycardia pacing from their implantable cardioverter defibrillator, or both.

69 referred for primary prevention implantable cardioverter defibrillator, we developed dual risk strat

70 (1) sudden cardiac death or (2) implantable cardioverter defibrillator-treated or hemodynamically un

71 e-saving preventive therapy, the implantable cardioverter defibrillator.

72 aker, and 1 has a single chamber implantable cardioverter defibrillator.

73 the need for primary prevention implantable cardioverter defibrillator.

74 ely to benefit from prophylactic implantable cardioverter defibrillator.

75 among index-patients without an implantable cardioverter-defibrillator (10/63, 16% versus 2/335, 0.6

76 who had a pacemaker (58%) or an implantable cardioverter-defibrillator (42%) that was not considered

77 biventricular pacemaker with an implantable cardioverter-defibrillator (CRT-D).

78 illator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD) alone are unclear.

79 ith defibrillator (CRT-D) versus implantable cardioverter-defibrillator (ICD) alone in CRT-eligible p

80 es with the benefits of CRT over implantable cardioverter-defibrillator (ICD) alone.

81 ligible for a primary prevention implantable cardioverter-defibrillator (ICD) are less likely than me

82 reassessed 40 days after MI for implantable cardioverter-defibrillator (ICD) candidacy.

83 ble clinical VTs based on stored implantable cardioverter-defibrillator (ICD) electrograms.

84 heter ablation and ultimately an implantable cardioverter-defibrillator (ICD) for prompt treatment of

85 The subcutaneous implantable cardioverter-defibrillator (ICD) has emerged as a novel

86 bility and value of prophylactic implantable cardioverter-defibrillator (ICD) implantation to prevent

87 SCD may be prevented by implantable cardioverter-defibrillator (ICD) implantation, but patie

88 patients likely to benefit from implantable cardioverter-defibrillator (ICD) implantation.

89 Background Patients undergoing implantable cardioverter-defibrillator (ICD) implantations have high

90 hat primary prevention use of an implantable cardioverter-defibrillator (ICD) improves survival in pa

91 The benefit of an implantable cardioverter-defibrillator (ICD) in patients with sympto

92 have established the role of the implantable cardioverter-defibrillator (ICD) in the treatment and pr

93 Implantable cardioverter-defibrillator (ICD) indications for primary

94 Penetration of the implantable cardioverter-defibrillator (ICD) into this patient popul

95 The implantable cardioverter-defibrillator (ICD) is effective for preven

96 of myocardial infarction with an implantable cardioverter-defibrillator (ICD) is frequent despite ant

97 The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective f

98 The implantable cardioverter-defibrillator (ICD) is the standard therapy

99 For the former, an implantable cardioverter-defibrillator (ICD) is typically required d

100 with an unused or malfunctioning implantable cardioverter-defibrillator (ICD) lead may have the lead

101 ations for CRT-D were matched to implantable cardioverter-defibrillator (ICD) patients without CRT de

102 ong-term nonfatal outcomes after implantable cardioverter-defibrillator (ICD) placement are poorly de

103 mended before primary prevention implantable cardioverter-defibrillator (ICD) placement.

104 ythmias (VAs) and should undergo implantable cardioverter-defibrillator (ICD) placement.

105 Implantable cardioverter-defibrillator (ICD) recipients require clos

106 onary intervention (CathPCI) and implantable cardioverter-defibrillator (ICD) registries of the NCDR.

107 nal Cardiovascular Data Registry implantable cardioverter-defibrillator (ICD) registry data between 2

108 y, and the Swedish Pacemaker and Implantable Cardioverter-Defibrillator (ICD) Registry.

109 en shown to reduce the burden of implantable cardioverter-defibrillator (ICD) shocks in small series

110 3 to 6 months after appropriate implantable cardioverter-defibrillator (ICD) shocks, contemporary da

111 patients who had a pacemaker or implantable cardioverter-defibrillator (ICD) that was "non-MRI-condi

112 ES patients, 21 had appropriate implantable cardioverter-defibrillator (ICD) therapy terminating pot

113 to amiodarone, placebo drug, or implantable cardioverter-defibrillator (ICD) therapy.

114 Most randomized trials on implantable cardioverter-defibrillator (ICD) use for primary prevent

115 The subcutaneous implantable cardioverter-defibrillator (ICD) was designed to avoid c

116 ces that include the transvenous implantable cardioverter-defibrillator (ICD) with or without cardiac

117 ic external defibrillator (AED), implantable cardioverter-defibrillator (ICD), or wearable cardiovert

118 In patients with an implantable cardioverter-defibrillator (ICD), shocks are associated

119 uld predict arrhythmic events in implantable cardioverter-defibrillator (ICD)-eligible cardiomyopathy

120 ict the survival benefit with an implantable cardioverter-defibrillator (ICD).

121 that was induced by means of an implantable cardioverter-defibrillator (ICD).

122 mias are common in patients with implantable cardioverter-defibrillator (ICD).

123 it a challenge for subcutaneous implantable cardioverter-defibrillator (S-ICD) screening.

124 The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to defi

125 This study evaluated the wearable cardioverter-defibrillator (WCD) for use and effectivene

126 The wearable cardioverter-defibrillator (WCD) has emerged as a means

127 ardioverter-defibrillator (ICD), or wearable cardioverter-defibrillator (WCD).

128 ased risk with CRT-D relative to implantable cardioverter-defibrillator -only.

129 chronization therapy (CRT-D) to an implanted cardioverter-defibrillator alters the risk of atrial fib

130 216 (45.3%) patients randomized to implanted cardioverter-defibrillator and 249 (50.3%) randomized to

131 56% among patients randomized to implantable cardioverter-defibrillator and CRT with defibrillator (C

132 treatment options including the implantable cardioverter-defibrillator and heart transplantation (HT

133 We excluded patients with prior implantable cardioverter-defibrillator and those randomized only to

134 nts receiving primary prevention implantable cardioverter-defibrillator and widening QRS.

135 isions about the placement of an implantable cardioverter-defibrillator are based on an estimate of a

136 er increase in RWT compared with implantable cardioverter-defibrillator at 12 months (4.6 +/- 6.8% vs

137 Patients who had an implantable cardioverter-defibrillator at the time of trial enrollme

138 Although an implantable cardioverter-defibrillator can save lives in individuals

139 (An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations [W

140 tment 18 experienced appropriate implantable cardioverter-defibrillator discharges, 2 underwent heart

141 ortality, composite end point of implantable cardioverter-defibrillator efficacy (arrhythmic deaths a

142 Patients with implantable cardioverter-defibrillator explantation had an incidence

143 nt of cardiac death, appropriate implantable cardioverter-defibrillator firing, resuscitated cardiac

144 ated with VA events (appropriate implantable cardioverter-defibrillator firings and arrhythmic sudden

145 and implantation of an automatic implantable cardioverter-defibrillator for prevention of sudden deat

146 lecting patients with DCM for an implantable cardioverter-defibrillator for primary prevention purpos

147 and the life-saving role of the implantable cardioverter-defibrillator highlight the importance of r

148 In the subcutaneous implantable cardioverter-defibrillator IDE study (Investigational De

149 agnetic resonance imaging before implantable cardioverter-defibrillator implantation for primary and

150 t for the decision making before implantable cardioverter-defibrillator implantation for the primary

151 thmias, sudden cardiac death, or implantable cardioverter-defibrillator implantation in a cohort of 2

152 dictor of survival benefit after implantable cardioverter-defibrillator implantation in patients with

153 he Guideline recommendations for implantable cardioverter-defibrillator implantation in patients with

154 most recent recommendations for implantable cardioverter-defibrillator implantation in these patient

155 cardiac disease and indication for implanted cardioverter-defibrillator implantation independently of

156 iles (P=0.91), and the effect of implantable cardioverter-defibrillator implantation on all-cause mor

157 us no-DFT testing at the time of implantable cardioverter-defibrillator implantation was performed to

158 cacy at the time of subcutaneous implantable cardioverter-defibrillator implantation without the need

159 ients who underwent subcutaneous implantable cardioverter-defibrillator implantation, 282 patients we

160 index-patients was modulated by implantable cardioverter-defibrillator implantation, but not by muta

161 lection of patients with DCM for implantable cardioverter-defibrillator implantation.

162 rect impact on the indication of implantable cardioverter-defibrillator implantation.

163 ant potential to guide patient selection for cardioverter-defibrillator implantation.

164 crucial to select candidates for implantable cardioverter-defibrillator implantation.

165 HF, mode of death, and effect of implantable cardioverter-defibrillator implantation.

166 creased risk of sudden cardiac death undergo cardioverter-defibrillator implantation; in patients wit

167 of a registry containing data on implantable cardioverter-defibrillator implantations from all implan

168 can usually be averted by implantation of a cardioverter-defibrillator in appropriate high-risk pati

169 We conducted the ICD2 trial (Implantable Cardioverter-Defibrillator in Dialysis Patients), a pros

170 uclear procedures, and pacemaker/implantable cardioverter-defibrillator insertion and repair.

171 (1.0 to 2.4 per 1000), pacemaker/implantable cardioverter-defibrillator insertions (1.6 to 4.4 per 10

172 udden cardiac death, appropriate implantable cardioverter-defibrillator intervention, and aborted car

173 er high-risk patients (13%) with implantable cardioverter-defibrillator interventions for ventricular

174 The implantable cardioverter-defibrillator is associated with changes in

175 0 VF events were recorded in the implantable cardioverter-defibrillator logs the 6 months preceding a

176 implantation of the subcutaneous implantable cardioverter-defibrillator may offer procedural and cosm

177 ation or death with CRT-D versus implantable cardioverter-defibrillator only therapy, whereas the eff

178 ischarged after index hospitalization with a cardioverter-defibrillator or cardiac resynchronization

179 Patients with a prior implantable cardioverter-defibrillator or sustained ventricular arrh

180 gate the impact of an additional implantable cardioverter-defibrillator over CRT, according to underl

181 0.0001); the frequency of VT in implantable cardioverter-defibrillator patients with recurrences was

182 dioversion in 2 patients and new implantable cardioverter-defibrillator placement in 2.

183 uartile range of 540) days after implantable cardioverter-defibrillator placement.

184 al Cardiovascular Data Registry, implantable cardioverter-defibrillator registry between 2006 and 200

185 Subcutaneous implantable cardioverter-defibrillator shock efficacy is associated

186 After implantable cardioverter-defibrillator shock, related HCU was common

187 den cardiac death or appropriate implantable cardioverter-defibrillator shock.

188 quency catheter ablation reduced implantable cardioverter-defibrillator shocks and VT episodes and im

189 the proportion of patients with implantable cardioverter-defibrillator shocks decreased from 81.2% t

190 cular tachycardia requiring >/=2 implantable cardioverter-defibrillator shocks occurred in 13 patient

191 Implantable cardioverter-defibrillator shocks seem to trigger a casc

192 cardiac arrest, and appropriate implantable cardioverter-defibrillator shocks) was 0.84 per 1000 HCM

193 ricular fibrillation-terminating implantable cardioverter-defibrillator shocks, and sudden cardiac de

194 to rates observed in transvenous implantable cardioverter-defibrillator studies.

195 d a legacy pacemaker or a legacy implantable cardioverter-defibrillator system.

196 h-quality evidence), appropriate implantable cardioverter-defibrillator therapy (5 studies; n=361; ha

197 have an attenuated benefit from implantable cardioverter-defibrillator therapy (older adults with mu

198 g-term mortality and appropriate implantable cardioverter-defibrillator therapy in ischemic cardiomyo

199 it is also well recognized that implantable cardioverter-defibrillator therapy is associated with bo

200 allenging because the benefit of implantable cardioverter-defibrillator therapy may not be uniform, p

201 Appropriate implantable cardioverter-defibrillator therapy was delivered in 23 p

202 om additional primary prevention implantable cardioverter-defibrillator therapy, as opposed to those

203 udden cardiac death, appropriate implantable cardioverter-defibrillator therapy, resuscitated cardiac

204 ry combined outcome (appropriate implantable cardioverter-defibrillator therapy, survived cardiac arr

205 Implantable cardioverter-defibrillator therapy.

206 , and 6 (23%) were suggested for implantable cardioverter-defibrillator therapy.

207 evaluated for primary prevention implantable cardioverter-defibrillator therapy.

208 ay not benefit from prophylactic implantable cardioverter-defibrillator therapy.

209 0s, hemodynamically unstable, or implantable cardioverter-defibrillator treated ventricular tachycard

210 (SCD, aborted SCD, sustained, or implantable cardioverter-defibrillator treated ventricular tachycard

211 resonance assessment may improve implantable cardioverter-defibrillator treatment decisions.

212 linical diagnosis of CPVT and an implantable cardioverter-defibrillator underwent a baseline exercise

213 of SCD and a low rate of primary implantable cardioverter-defibrillator utilization in patients with

214 1.13-1.99], P<0.01) but neither implantable cardioverter-defibrillator utilization nor ventricular a

215 ate (4.0%) of primary prevention implantable cardioverter-defibrillator utilization.

216 Implantation of an implantable cardioverter-defibrillator was considered but was ultima

217 uration of HF, and the effect of implantable cardioverter-defibrillator was not modified by the durat

218 h defibrillator (CRT-D; CRT with implantable cardioverter-defibrillator) was associated with a greate

219 iac resynchronization therapy or implantable cardioverter-defibrillator).

220 total of 81 patients received an implantable cardioverter-defibrillator, 34 were successfully defibri

221 sease, cardiac resynchronization implantable cardioverter-defibrillator, and VT storm despite greater

222 B patients, CRT-D, compared with implantable cardioverter-defibrillator, was associated with a signif

223 (29%) of 78 IVF patients with an implantable cardioverter-defibrillator, with a median of 3 appropria

224 The CRT-D versus implantable cardioverter-defibrillator-only risk for first and subse

225 t techniques of the subcutaneous implantable cardioverter-defibrillator.

226 cient to justify placement of an implantable cardioverter-defibrillator.

227 e subcutaneous ICD (S-ICD), and the wearable cardioverter-defibrillator.

228 s a class I indication for implantation of a cardioverter-defibrillator.

229 ympathetic denervation and implantation of a cardioverter-defibrillator.

230 l myectomy; 14 (25%) received an implantable cardioverter-defibrillator; 1 underwent cardiac transpla

231 onresynchronization defibrillator (implanted cardioverter-defibrillator; n=477) within the predefined

232 the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD), a prospective

233 mote patient monitoring (RPM) of implantable cardioverter defibrillators (ICD) and all-cause mortalit

234 in patients with pacemakers and implantable cardioverter defibrillators (ICDs) and evaluate associat

235 ary prophylactic implantation of implantable cardioverter defibrillators (ICDs) experiences malignant

236 have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary preventio

237 Clinical trials of implantable cardioverter defibrillators (ICDs) for primary preventio

238 risk, prophylactic insertion of implantable cardioverter defibrillators (ICDs) reduces mortality.

239 roup comprised 160 patients with implantable cardioverter defibrillators (ICDs), of whom 94 patients

240 e at the time of implantation of implantable cardioverter defibrillators (ICDs).

241 he recent advent of subcutaneous implantable cardioverter defibrillators (S-ICDs) has provided invest

242 ficacy/clinical effectiveness of implantable cardioverter defibrillators and understand why these dev

243 tification of primary prevention implantable cardioverter defibrillators considering the competing ri

244 Women receiving implantable cardioverter defibrillators for primary prevention of su

245 hythmias, as well as the role of implantable cardioverter defibrillators for primary prevention.

246 tients were excluded if they had implantable cardioverter defibrillators or permanent pacemakers.

247 gs implanted with single-chamber implantable cardioverter defibrillators to record ventricular arrhyt

248 Implantable cardioverter defibrillators were common despite numerous

249 Implantable cardioverter defibrillators were placed in 121 (54%) and

250 episodes (tracked by indwelling implantable cardioverter defibrillators) or any reduction in PVC bur

251 rizes the existing literature on implantable cardioverter defibrillators, biventricular pacemakers, m

252 ock following primary prevention implantable cardioverter defibrillators.

253 ted the choice of candidates for implantable cardioverter defibrillators.

254 to Assess the Efficacy of ICDs [Implantable Cardioverter Defibrillators] in Patients With Non-Ischem

255 hospitals); 2) ICD Registry for implantable cardioverter-defibrillators (158,649 procedures performe

256 Antitachycardia pacing (ATP) in implantable cardioverter-defibrillators (ICD) decreases patient shoc

257 Remote monitoring (RM) of implantable cardioverter-defibrillators (ICD) is an established tech

258 I) of patients with conventional implantable cardioverter-defibrillators (ICD) is contraindicated.

259 patients with primary prevention implantable cardioverter-defibrillators (ICD) may experience an impr

260 Implantable cardioverter-defibrillators (ICDs) are a standard means

261 Older recipients of implantable cardioverter-defibrillators (ICDs) are at increased risk

262 Although implantable cardioverter-defibrillators (ICDs) are frequently viewed

263 Background Implantable cardioverter-defibrillators (ICDs) are indicated in pati

264 Implantable cardioverter-defibrillators (ICDs) are not recommended w

265 sudden cardiac death (SCD), and implantable cardioverter-defibrillators (ICDs) are the mainstay of t

266 stay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used but often ca

267 The effectiveness of implantable cardioverter-defibrillators (ICDs) for primary preventio

268 Clinical trials of implantable cardioverter-defibrillators (ICDs) for secondary prevent

269 Implantable cardioverter-defibrillators (ICDs) have a role in preven

270 The programming of implantable cardioverter-defibrillators (ICDs) influences inappropri

271 Although implantable cardioverter-defibrillators (ICDs) reduce sudden death,

272 al fibrillation in patients with implantable cardioverter-defibrillators (ICDs), but ventricular proa

273 n management strategy, including implantable cardioverter-defibrillators (ICDs), heart transplantatio

274 ecific, strategic programming of implantable cardioverter-defibrillators (ICDs), including faster det

275 utcomes among patients receiving implantable cardioverter-defibrillators (ICDs).

276 ecurrence of VT in patients with implantable cardioverter-defibrillators (ICDs).

277 treatment for patients receiving implantable cardioverter-defibrillators (ICDs).

278 aries widely among recipients of implantable cardioverter-defibrillators (ICDs).

279 ts received secondary prevention implantable cardioverter-defibrillators (long QT syndrome, 9; Brugad

280 Transvenous implantable cardioverter-defibrillators (TV-ICDs) improve survival i

281 tients (123 pacemakers [57%]; 92 implantable cardioverter-defibrillators [43%]).

282 ers alone in 350 (58%) patients, implantable cardioverter-defibrillators alone in 25 (4%) patients, l

283 Implantable cardioverter-defibrillators are indicated for prevention

284 Implantable cardioverter-defibrillators are used to prevent sudden c

285 th dilated cardiomyopathy (DCM), implantable cardioverter-defibrillators do not increase longevity.

286 risk patients and utilization of implantable cardioverter-defibrillators for prevention of sudden dea

287 risk patients who benefited from implantable cardioverter-defibrillators for sudden death prevention,

288 ents implanted with subcutaneous implantable cardioverter-defibrillators from 2 hospitals between 200

289 ve cohort study of patients with implantable cardioverter-defibrillators identified from commercial a

290 ong 176 patients with dual-chamber implanted cardioverter-defibrillators in Boston, Massachusetts bet

291 ac resynchronization therapy and implantable cardioverter-defibrillators may be required to prevent l

292 Implantable cardioverter-defibrillators were placed in 59% of patien

293 s and lives potentially saved by implantable cardioverter-defibrillators, all de novo implantations f

294 Pharmacotherapy, implantable cardioverter-defibrillators, and left cardiac sympatheti

295 In patients with implantable cardioverter-defibrillators, healthcare utilization (HCU

296 Device therapy, primarily with implantable cardioverter-defibrillators, is often recommended for pa

297 ourse for CIEDs, pacemakers, and implantable cardioverter-defibrillators, respectively.

298 in patients with advanced HF and implantable cardioverter-defibrillators.

299 tor and guide the optimal use of implantable cardioverter-defibrillators.

300 by cardiac resynchronisation and implantable cardioverter-defibrillators; neurohumoral modification b